CSA Medical Inc. has been touting positive results of its feasibility study of the RejuvenAir® Metered Cryospray™ system at the 2018 European Respiratory Society (ERS) Congress in Paris.
CSA Medical’s Liquid Nitrogen (LN2) spray has a boiling point of -196oC to ablate unwanted benign and malignant tissue. The company has developed a proprietary interventional spray cryotherapy technology platform that delivers this spray cryogen inside the body to flash freeze and destroy unwanted tissue. In the RejuvenAir® Metered Cryospray™ System, liquid nitrogen is sprayed in a circumferential pattern within the airway. The rapid freezing of the epithelial layer of the airway walls is thought to destroy the mucus-producing goblet cells while preserving the extracellular matrix, thereby enabling the regrowth of healthy cells.
The RejuvenAir® System is currently under clinical investigation and is not commercially available, hence the excitement at positive clinical study news. At 6-month follow up after treatment with RejuvenAir® 30 patients showed clinically meaningful improvement in Quality of Life, a strong safety profile and high degree of toleration.
Dirk-Jan Slebos, M.D., PhD of the Department of Pulmonary Diseases, at the University Medical Center Groningen, Netherlands reported that; “The RejuvenAir therapy appears to have a beneficial response with a decrease in cough and mucus production even in our patients who had optimized medical management. The overall improvement in breathing resulted in increased physical activity supporting the potential for RejuvenAir to measurably improve quality of life in chronic bronchitis patients.”
Professor Pallav Shah, M.D., FRCP from the Royal Brompton, London added; “RejuvenAir Metered Cryospray can be safely delivered in patients with COPD and demonstrates clinical meaningful improvements in quality of life and symptom scores (SGRQ and CAT) out to 6 months and is a promising new therapy for the millions of people who suffer from chronic bronchitis.”
Wendelin Maners, CSA Medical’s Chief Commercial Officer, stated; “We are encouraged by these positive safety and feasibility results and we’re moving forward with plans to initiate a worldwide pivotal study of RejuvenAir in chronic bronchitis in 2019. We look forward to advancing this novel therapy toward commercialization to provide relief to the millions of patients suffering from COPD with chronic bronchitis.”
Source: PR Newswire